Reuters: BridgeBio oral drug improved growth in achondroplasia study | Source Library

StudyPeer-reviewed research publisher

Source type: Study
Access type: Publisher
Publisher: Reuters
Date: 2026-02-12
Added: 2026-06-30

Trust profile

VV Source Trust Matrix v1.0

VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.

Peer-reviewed research publisher

Publisher type: Peer-reviewed journal
Bias profile: Moderate

This source is strongest for clinical outcomes and mechanism and weaker for regulatory status and trial discovery.

VV Source Fit Score 1.0

Fit by use case

Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.

Frameworks ->

Regulatory status: 65/100; Context Source
Clinical outcomes: 92/100; Primary Anchor
Mechanism: 90/100; Primary Anchor
Safety: 86/100; Strong Support
Consumer context: 72/100; Context Source
Trial discovery: 65/100; Context Source

Best used for

Primary studies
Systematic reviews
Mechanistic research

Weak for

Regulatory status
Universal consumer recommendations

Used in Viral Vitalism

Primary sourcebrief1 reference

Oral FGFR3 Drug Shows Phase 3 Benefit in Children With Achondroplasia

Roles: Primary source

Show section-level references

BridgeBio reported that oral infigratinib met the primary endpoint in Phase 3 PROPEL 3, improving annualized height velocity versus placebo in children with achondroplasia.

Related studies

No structured study record is currently attached to this source.